A recent study by Upstate Medical University links recreational cannabis use to a significant reduction in the risk of subjective cognitive decline (SCD), suggesting a potential 96% decrease in risk compared to non-users. Despite the lack of evidence supporting CBD's role in cognitive health, the study highlights cannabis's overall protective properties against cognitive decline.
A recent study conducted by researchers at Upstate Medical University establishes a link between recreational cannabis use and a reduced risk of cognitive decline.
According to the study, compared to non-users, non-medical cannabis consumption is significantly associated with a 96% reduction in the risks of subjective cognitive decline (SCD). Individuals suffering from SCD are at an increased risk of dementia, a condition for which there are currently no definitive prevention strategies.
For more news like this, along with all the latest in legalization, research, and lifestyle, download our free cannabis news app.
The study, led by MPH student Zhi Chen and Professor Roger Wong, examined three key aspects of cannabis consumption: type (medical or non-medical), frequency, and method (smoking, vaping, eating, or dabbing). These dimensions were scrutinized to understand their impact on the cognitive health of middle-aged and older adults.
Professor Wong emphasized the need for longitudinal studies to fully grasp the implications of non-medical cannabis use on cognition over time.
“The main finding is that cannabis could have a protective effect on our cognition,” said Professor Wong, “but it is really crucial to conduct longitudinal studies, as this is just a snapshot from 2021.”
The study’s results challenge conventional wisdom about cannabis consumption and cognitive health, particularly regarding the frequency and method of use. While previous studies involving younger populations suggested negative links between cannabis and brain health, the research from Upstate Medical University indicates age-related nuances in these relationships.
Despite the protective association observed with non-medical cannabis use, the study highlighted some limitations, such as the absence of state-specific cannabis regulations in the analysis. However, the use of a national dataset helps to better generalize the results.
Professor Wong noted that the protection gap between medical and non-medical use of cannabis could be attributed to the varying cannabinoid compositions in different types of cannabis. Medical cannabis generally contains more CBD and less THC than recreational variants.
Furthermore, the study suggests that the observed protective effects against cognitive decline might stem from cannabis properties that improve sleep and reduce stress. Non-medical users often turn to cannabis to alleviate their sleep issues and chronic stress, both of which are involved in cognitive decline.
Contrary to expectations, the study did not find substantial evidence supporting the idea that CBD significantly contributes to cognitive health benefits. Professor Wong suggests that the protective effects might be more closely related to other components of cannabis consumption.
This research opens up new avenues for understanding the potential cognitive benefits of cannabis, especially in non-medical contexts. It underscores the importance of further investigations into how different cannabis components and consumption methods might influence cognitive health across various age groups.
—
(Featured image by Google DeepMind via Unsplash)
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Ontario is investing $31 million over the next three years to enhance efforts against illegal…
Frankfurt and Hanover are launching five-year pilot projects for legal, regulated cannabis sales to adults,…
Italy's Regional Administrative Court suspended the Health Ministry's decree labeling CBD as a narcotic, pending…
This November, five U.S. states will vote on measures related to legalizing recreational or medical…
The European Commission has launched an investigation into Italy after its recent proposal to ban…
A new study has found that prolonged use of high-THC cannabis leaves a unique mark…